ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

SAFETY AND EFFECTIVENESS OF METFORMIN IN OBESE FEMALES SUFFERING FROM POLYCYSTIC OVARY SYNDROME

Dr Irum Saeed, Dr Muhammad Nauman Bashir, Dr Fouzia Shaheen

Objective: This research work aimed to assess the safety & effectiveness of the metformin in obese females suffering from POS (Polycystic Ovary Syndrome). Methodology: We evaluated 44 obese females suffering from Polycystic Ovary Syndrome in this open label research work. We prescribed metformin five hundred milligram 3 times in a day for complete 6 months. Assessment of the main outcomes as the level of the fasting insulin, fasting glucose level of plasma, sensitivity of insulin, weight, body mass index, ratio of waist to hip and features of ultrasonography of obese females. The next outcomes were BP, menses cycles & hirsutism. Then we assessed the intervention safety in accordance with the self-reported side effects & performing renal as well as hepatic profiles. We evaluated every patient on monthly basis. Results: Total 90.90% (n: 40) patients completed this research work. At the completion of 6 months, we found an important impact of the medicine on all the important features. Weight reduced from 85.70 ± 1.03 to 84.380 ±1.020, body mass index from 33.20 ± 0.320 to 32.80 ± 0.330 & ratio of waist to hip from 0.850 ± 0.003 to 0.830 ± 0.002. Features of ultrasonography, BP also displayed important improvement. Menses cycles, hirsutism & metabolic features as level of serum insulin, glucose & HOMA index were also present with improvement. All the patients tolerated the medicine in a well manner. We observed no change in the urea of blood, level of ALT and levels of serum creatinine. Conclusion: Metformin is very secure & effectual medicine for the therapy of the obese females suffering from polycystic ovary syndrome. Keywords: Polycystic Ovary Syndrome, Creatinine, Ultrasonography, Hirsutism, Metabolic.

FULL TEXT